评估新辅助化疗乳腺癌患者乳腺MRI上无同时异常强化的持续性T1加权病灶:对完全病理缓解的意义
回顾性分析2011年1月至2018年12月接受新辅助化疗及手术的294例乳腺癌患者,比较化疗后MRI有无持续性T1病灶两组的病理完全缓解与影像缓解。有持续性T1病灶组病理完全缓解率14% vs 无病灶组39%(p<0.001),影像缓解率69% vs 93%(p<0.001);多因素分析OR 0.37(95%CI 0.18-0.76,p=0.007)。作者认为持续性T1病灶与较低的完全病理及影像缓解率相关,应作为指导新辅助化疗后治疗决策的关键因素。
要点
- 化疗后乳腺MRI上无异常强化的持续性T1病灶提示病理完全缓解可能性降低(14% vs 39%,p<0.001)。
- 有持续性T1病灶者影像缓解率亦较低(69% vs 93%,p<0.001)。
- 除残留强化外,还应考虑有无残留T1病灶以评估影像缓解。
核心结论
- 化疗后乳腺MRI上无同时异常强化的持续性T1加权病灶与较低的病理完全缓解率和影像缓解率相关(OR 0.37,95%CI 0.18-0.76,p=0.007)。
研究设计与样本
- 回顾性研究,纳入2011年1月至2018年12月接受新辅助化疗及手术且化疗前后均行乳腺MRI的乳腺癌患者,294例符合纳入标准,其中157例有持续性T1病灶、137例无。
关键影像表现/征象
- 化疗后MRI上持续性T1加权病灶不伴同时异常强化。
- 有持续性T1病灶组病理完全缓解率14%,无病灶组39%(p<0.001)。
- 有持续性T1病灶组影像缓解率69%,无病灶组93%(p<0.001)。
诊断标准与关键数值
- 持续性T1病灶组病理完全缓解率14% vs 无持续性T1病灶组39%,p<0.001。
- 持续性T1病灶组影像缓解率69% vs 无持续性T1病灶组93%,p<0.001。
- 多因素分析中持续性T1病灶与病理完全缓解的OR为0.37(95%CI 0.18-0.76),p=0.007。
临床应用与阅片要点
- 作者的结果提示,在将无残留强化等同于完全影像缓解的惯例之外,还应考虑有无残留T1病灶。
- 作者指出持续性T1病灶是重要的临床标志物,与病理完全缓解呈负相关,应作为指导新辅助化疗后治疗决策的关键因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aims to determine whether persistent T1-weighted lesions signify a complete pathological response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy and surgery, and to evaluate their correlation with imaging responses on MRI.
MATERIALS AND METHODS: A retrospective review was conducted on data from breast cancer patients treated between January 2011 and December 2018. Patients who underwent breast MRI and pre- and post-neoadjuvant chemotherapy followed by surgery were included. Those with distant metastasis, no planned surgery, pre-surgery radiation, ineligibility for neoadjuvant chemotherapy, or unavailable surgical pathology were excluded. Groups with and without persistent T1-weighted lesions were compared using the chi-square test for categorical variables and the Student t test or Wilcox rank sum test for continuous variables. Univariate logistic regression was used to evaluate the association of the final pathological response with the presence of T1-persistent lesion and other characteristics.
RESULTS: Out of 319 patients, 294 met the inclusion criteria (breast cancer patients treated with neoadjuvant chemotherapy and subsequent surgery); 157 had persistent T1 lesions on post-chemotherapy MRI and 137 did not. A persistent T1 lesion indicated reduced likelihood of complete pathological response (14% vs. 39%, p < 0.001) and imaging response (69% vs. 93%, p < 0.001). Multivariable analysis confirmed these findings: OR 0.37 (95% CI 0.18-0.76), p = 0.007. No other characteristics correlated with T1 residual lesions.
CONCLUSION: Persistent T1-weighted lesions without associated abnormal enhancement on post-treatment breast MRI correlate with lower complete pathological and imaging response rates.
CLINICAL RELEVANCE STATEMENT: The study underscores the importance of persistent T1-weighted lesions on breast MRI as vital clinical markers, being inversely related to a complete pathological response following neoadjuvant chemotherapy; they should be a key factor in guiding post-neoadjuvant chemotherapy treatment decisions.
KEY POINTS: • Persistent T1 lesions on post-chemotherapy breast MRI indicate a reduced likelihood of achieving a complete pathological response (14% vs. 39%, p < 0.001) and imaging response (69% vs. 93%, p < 0.001). • Through multivariable analysis, it was confirmed that the presence of a persistent T1 lesion on breast MRI post-chemotherapy is linked to a decreased likelihood of complete pathological response, with an odds ratio (OR) of 0.37 (95% CI 0.18-0.76; p = 0.007). • In addition to the convention of equating the absence of residual enhancement to complete imaging response, our results suggest that the presence or absence of residual T1 lesions should also be considered.
引用
- Goulam-Houssein S, Ye XY, Fleming R, et al. Evaluating persistent T1-weighted lesions without concurrent abnormal enhancement on breast MRI in neoadjuvant chemotherapy patients: implications for complete pathological response. Eur Radiol. 2024. PMID: 38491128. doi:10.1007/s00330-024-10695-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。